Characterization and treatment of chronic active Epstein-Barr virus disease: A 28-year experience in the United States

Blood

Volumn 117, Issue 22, 2011, Pages 5835-5849

  Cohen, Jeffrey I ^a   Jaffe, Elaine S ^b   Dale, Janet K ^a   Pittaluga, Stefania ^b   Heslop, Helen E ^c   Rooney, Cliona M ^c   Gottschalk, Stephen ^c   Bollard, Catherine M ^c   Rao, V Koneti ^a   Marques, Adriana ^a   Burbelo, Peter D ^d   Turk, Siu Ping ^a   Fulton, Rachael ^a   Wayne, Alan S ^b   Little, Richard F ^b   Cairo, Mitchell S ^e   El Mallawany, Nader K ^e   Fowler, Daniel ^b   Sportes, Claude ^b   Bishop, Michael R ^b   Wilson, Wyndham ^b   Straus, Stephen E ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ASPARAGINASE; AZATHIOPRINE; BETA INTERFERON; BORTEZOMIB; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DESCICLOVIR; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GAMMA INTERFERON; GANCICLOVIR; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; VALACICLOVIR; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CELL LOSS; CHILD; CHRONIC ACTIVE EPSTEIN BARR VIRUS DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; EPSTEIN BARR VIRUS INFECTION; FEMALE; FEVER; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HUMAN; IMMUNOGLOBULIN DEFICIENCY; JAPAN; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MALE; NATURAL KILLER CELL; PANCYTOPENIA; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SPLENECTOMY; SPLENOMEGALY; TREATMENT RESPONSE; UNITED STATES;

EID: 79957990581     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-316745     Document Type: Article

References (48)

1. Okano M, Matsumoto S, Osato T, Sakiyama Y, Thiele GM, Purtilo DT. Severe chronic active Epstein-Barr virus infection syndrome. Clin Microbiol Rev. 1991;4(1):129-135. (Pubitemid 21920390)
2. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98(2):280-286.
3. Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol. 2005;80(1):64-69. (Pubitemid 41254271)
4. Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol. 2009;20(9):1472-1482.
5. Kimura H, Morishima T, Kanegame H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infec Dis. 2003;187(4):527-533. (Pubitemid 36250015)
6. Quintanilla-Martinez L, Kumar S, Fend F, et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood. 2000;96(2):443-451. (Pubitemid 30463361)
7. Schooley RT, Carey RW, Miller G, et al. Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy. Ann Intern Med. 1986;104(5):636-643. (Pubitemid 16078467)
8. Fujieda M, Wakiguchi H, Hisakawa H, Kubota H, Kurashige T. Defective activity of Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes in children with chronic active EBV infection and in their parents. Acta Paediatr Jpn. 1993;35(5):394-399. (Pubitemid 23293465)
9. Sugaya N, Kimura H, Hara S, et al. Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T cells in patients with chronic active EBV infection. J Infect Dis. 2004;190(5):985-988. (Pubitemid 39120978)
10. Joncas J, Monczak Y, Ghibu F, et al. Brief report: killer cell defect and persistent immunological abnormalities in two patients with chronic active Epstein-Barr virus infection. J Med Virol. 1989;28(2):110-117. (Pubitemid 19189044)
11. Katano H, Ali MA, Patera AC, et al. Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. Blood. 2004;103(4):1244-1252. (Pubitemid 38168634)
12. Gotoh K, Ito Y, Shibata-Watanabe Y, et al. Clinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation. Clin Infect Dis. 2008;46(10):1525-1534. (Pubitemid 351706733)
13. Sato E, Ohga S, Kuroda H, et al. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol. 2008;83(9):721-727.
14. Kawa K, Sawada A, Sato M, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant. 2011;46(1):77-83.
15. Straus SE. Acute progressive Epstein-Barr virus infections. Annu Rev Med. 1992;43:437-449.
16. El-Mallawany NK, Geller L, Bollard CM, et al. Long term remission in a child with refractory EBV(+) hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV(+)-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy [published online ahead of print July 26, 2010]. Bone Marrow Transplant. doi:10.1038/bmt.2010-176.
17. Kenagy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-Keener MM, Storch GA. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation. 1995;60(6):547-554.
18. Calattini S, Sereti I, Scheinberg P, Kimura H, Childs RW, Cohen JI. Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders using Immuno-FISH. Blood. 2010;116(22):4546-4559.
19. Savoldo B, Goss J, Liu Z, et al. Generation of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells (CTL) for adoptive immunotherapy in solid organ transplant recipients. Transplantation. 2001;72(6):1078.
20. Sashihara J, Burbelo PD, Savoldo B, Pierson TC, Cohen JI. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. Virology. 2009;391(2):249-256.
21. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110(8):2838-2845. (Pubitemid 350006936)
22. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925-935.
23. Kimura H, Hoshino Y, Hara S, et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. J Infect Dis. 2005;191(4):531-539. (Pubitemid 40216668)
24. Ohga S, Nomura A, Takada H, et al. Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. J Infect Dis. 2001;183(1):1-7. (Pubitemid 32043035)
25. Wakiguchi H, Fujieda M, Matsumoto K, Ohara Y, Wakiguchi A, Kurashige T. Defective killer cell activity in patients with chronic active Epstein-Barr virus infection. Acta Med Okayama. 1988;42(3):137-142.
26. Callan MF, Steven N, Krausa P, et al. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med. 1996;2(8):906-911. (Pubitemid 26296762)
27. Iwata S, Wada K, Tobita S, et al. Quantitative analysis of Epstein-Barr virus (EBV)-related gene expression in patients with chronic active EBV infection. J Gen Virol. 2010;91(Pt 1):42-50.
28. Sakai Y, Ohga S, Tonegawa Y, et al. Interferon-alpha therapy for chronic active Epstein-Barr virus infection: potential effect on the development of T-lymphoproliferative disease. J Pediatr Hematol Oncol. 1998;20(4):342-346. (Pubitemid 28483344)
29. Kawa-Ha K, Franco E, Doi S, et al. Successful treatment of chronic active Epstein-Barr virus infection with recombinant interleukin-2. Lancet. 1987;1(8525):154. (Pubitemid 17015834)
30. Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood. 1999;93(6):1869-1874. (Pubitemid 29128488)
31. Kuzushima K, Yamamoto M, Kimura H. Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T cells from an HLA-matched sibling to a patients with severe chronic active EBV infection. Clin Exp Immunol. 1996;103(2):192-198.
32. Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002;100(12):4059-4066. (Pubitemid 35396873)
33. Okamura T, Hatsukawa Y, Arai H, Inoue M, Kawa K. Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. Lancet. 2000;356(9225):223-234.
34. Fujii N, Takenaka K, Hiraki A, et al. Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection. Bone Marrow Transplant. 2000;26(7):805-808.
35. Taketani T, Kikuchi A, Inatomi J, et al. Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2002;29(6):531-533. (Pubitemid 34428725)
36. Yasui M, Okamura T, Sakata N, et al. CD34+ progenitor cell transplantation from HLA-mismatched donors to two patients with chronic active Epstein-Barr virus infection. Rinsho Ketsueki. 2001;42(11):1111-1116.
37. Okamura T, Kishimoto T, Inoue M, et al. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant. 2003;31(2):105-111. (Pubitemid 36240501)
38. Sakata N, Sato E, Sawada A, Yasui M, Inoue M, Kawa K. Chronic active Epstein-Barr virus infection treated with reduced intensity stem cell transplantation. Rinsho Ketsueki. 2004;45(5):393-396.
39. Ebihara Y, Manabe A, Tanaka R, et al. Successful treatment of natural killer (NK) cell leukemia following a long-standing chronic active Epstein-Barr virus (CAEBV) infection with allogeneic bone marrow transplantation. Bone Marrow Transplant. 2003;31(12):1169-1171. (Pubitemid 36857376)
40. Uehara T, Nakaseko C, Hara S, et al. Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection. Am J Hematol. 2004;76(4):368-372. (Pubitemid 38988622)
41. Takeoka Y, Nakao Y, Ueda M, et al. A case of a long-time survivor with chronic active Epstein-Barr virus infection. Eur J Haematol. 2004;72(1):73-76. (Pubitemid 38161118)
42. Ishimura M, Ohga S, Nomura A, et al. Successful umbilical cord blood transplantation for severe chronic active Epstein-Barr virus infection after the double failure of hematopoietic stem cell transplantation. Am J Hematol. 2005;80(3):207-212. (Pubitemid 41579543)
43. Iguchi A, Kobayashi R, Sato TZ, Nakajima M, Kaneda M, Ariga T. Successful report of reduced-intensity stem cell transplantation from unrelated umbilical cord blood in a girl with chronic active Epstein-Barr infection. J Pediatr Hematol Oncol. 2006;28(4):254-256. (Pubitemid 43791836)
44. Nakagawa M, Hashino S, Takahata M, et al. Successful reduced-intensity stem cell transplantation with cord blood for a poor-prognosis adult with refractory chronic active Epstein-Barr virus infection. Int J Hematol. 2007;85(5):443-445. (Pubitemid 47457457)
45. Yoshiba F, Hagihara M, Tazume K, et al. Complete resolution of severe chronic active Epstein-Barr virus infection by cultured, activated donor T lymphocyte infusion after nonmyeloablative stem cells allografting. Bone Marrow Transplant. 2003;32(1):107-110. (Pubitemid 36850288)
46. Miyamura T, Chayama K, Wada T, et al. Two cases of chronic active Epstein-Barr virus infection in which EBV-specific cytotoxic T lymphocyte was induced after allogeneic bone marrow transplantation. Pediatr Transplant. 2008;12(5):588-592.
47. Matsunaga T, Kurosawa H, Okuya M, et al. Chronic active Epstein-Barr virus infection with mosquito allergy successfully treated with reduced-intensity unrelated allogeneic bone marrow transplantation in a boy. Pediatr Transplant. 2009;13(2):231-234.
48. Sonke GS, Ludwig I, van Oosten H, et al. Poor outcomes of chronic active Epstein-Barr virus infection and hemophagocytic lymphohistiocytosis in non-Japanese adult patients. Clin Infect Dis. 2008;47(1):105-108. (Pubitemid 351920595)